On April 30, 2020, the U.S. Food and Drug Administration (FDA) quickly and succinctly denied MAPS’ request for a meeting to resolve the clinical hold issues, citing that the meeting request did not propose to discuss new information.
On April 30, 2020, the U.S. Food and Drug Administration (FDA) quickly and succinctly denied MAPS’ request for a meeting to resolve the clinical hold issues, citing that the meeting request did not propose to discuss new information.